

**State communication**

A message from New York State Department of Health

**New York Medicaid Guidance for Billing Monoclonal Antibody Treatments**

New York State (NYS) Medicaid will reimburse NY Medicaid enrolled pharmacies for administration or dispensing of COVID-19 therapeutics, including monoclonal antibody (mAb) treatments with no member cost share.

The mAb must be approved or granted Emergency Use Authorization through the FDA and must be ordered and administered in accordance with FDA approval or authorization. Evusheld (tixagevimab and cilavimab) must be prescribed for an individual patient by a physician, nurse practitioner, or physician assistant licensed or authorized under New York State law to prescribe monoclonal antibodies for prevention of COVID-19.

mAb Name*	Setting
Evusheld (tixagevimab and cilavimab)	Health Care
Evusheld (tixagevimab and cilavimab)	Home

\*Please refer to NYS website for updates on included therapies:

[health.ny.gov/health\\_care/medicaid/covid19/guidance/docs/guidance\\_for\\_therapy\\_at\\_pharmacies.pdf](https://health.ny.gov/health_care/medicaid/covid19/guidance/docs/guidance_for_therapy_at_pharmacies.pdf)

A Plan Sponsor may choose not to cover COVID-19 mAb therapy dispensing and administration through the pharmacy benefit. Rely upon the claim adjudication response for determination of coverage prior to reconstitution and administration.

Providers submitting claims for COVID-19 mAb therapy paid for by the federal government or paid for by any program supplying Provider with no associated cost (zero cost) COVID-19 mAb therapy must submit claims with either \$0.01 in the Ingredient Cost Submitted field (NCPDP field # 409-D9) or the combination of \$0.00 in the Ingredient Cost Submitted field and a value of '15' in the Basis of Cost Determination field (NCPDP # field 423-DN).

**Claims Submission Information**

Submit 'MA' in the Professional Service Code field (NCPDP field # 440-E5) of the DUR/PPS Segment along with a positive amount in the Incentive Amount Submitted field (NCPDP field # 438-E3) of the Pricing Segment when administering infusible and injectables.

Submit the appropriate Quantity (e.g., 3 ml) and Days Supply of '1'. Inappropriate Quantities or Days Supply may cause the claim to reject.

Field #	NCPDP Segment & Field Name	Required Vaccine Administration Information for Processing
440-E5	DUR/PPS Segment Professional Service Code	MA (Medication Administration)
409-D9	Pricing Segment Ingredient Cost Submitted	≥\$0.01 Submit Therapy Cost (If government-supplied, see below)
438-E3	Pricing Segment Incentive Amount Submitted	≥\$0.01 Submit Administration Fee (Equal or greater than expected Applicable Administration Fee)
426-DQ	Pricing Segment Usual and Customary Charge	≥ Incentive Amount Submitted
307-C7	Patient Segment	12

<https://providerpublic.mybcbswny.com>

Amerigroup Partnership Plan, LLC provides management services for Highmark Blue Cross Blue Shield of Western New York's managed Medicaid. Amerigroup Partnership Plan, LLC brinda servicios administrativos para Medicaid administrado de Highmark Blue Cross Blue Shield of Western New York.

Highmark Blue Cross Blue Shield of Western New York is a trade name of Highmark Western and Northeastern New York Inc., an independent licensee of the Blue Cross Blue Shield Association. Highmark Blue Cross Blue Shield of Western New York es un nombre comercial de Highmark Western y Northeastern New York Inc., un licenciatario independiente de Blue Cross Blue Shield Association.

	Place of Service	<b>(If submitting for Home Setting)</b>
--	------------------	---

**Government-Supplied COVID-19 Therapy Programs**

When submitting administration claims for a COVID-19 mAb therapy provided without cost through a government program, pharmacies must populate specific values in the following fields:

Field #	NCPDP Field Name	Required Vaccine Administration Information for Processing
409-D9	<b>Ingredient Cost Submitted</b>	<b>\$0.00</b>
423-DN	<b>Basis of Cost Determination</b>	<b>15</b> (Free product or no associated cost)

As an example, included is a section of a Payer Sheet. Only NCPDP Segments/Fields pertinent to special COVID-19 mAb therapy billing instructions are shown.

<b>CLAIM Segment</b> Segment Identification (NCPDP field # 111-AM) = '07'				
Field #	NCPDP Field Name	Value	Payer Usage	Payer Situation
436-E1	PRODUCT/SERVICE ID QUALIFIER	03	M	NDC
407-D7	PRODUCT/SERVICE ID	0310-7442-02	M	Evusheld NDC shown as example
442-E7	QUANTITY DISPENSED	3 ml	R	
405-D5	DAYS SUPPLY	1	R	

<b>DUR/PPS Segment</b> Segment Identification (NCPDP field # 111-AM) = '08'				
Field #	NCPDP Field Name	Value	Payer Usage	Payer Situation
473-7E	DUR / PPS Code Counter	1	R	
440-E5	Professional Service Code	MA	R	MA (Medication Administration)

<b>Pricing Segment</b> Segment Identification (NCPDPD field # 111-AM) = '11'				
Field #	NCPDP Field Name	Value	Payer Usage	Payer Situation
409-D9	INGREDIENT COST SUBMITTED	\$0.01	R	Use \$0.00 for free product
438-E3	INCENTIVE AMOUNT SUBMITTED		R	
426-DQ	USUAL AND CUSTOMARY CHARGE		R	
430-DU	GROSS AMOUNT DUE		R	
423-DN	Basis of Cost Determination	01	R	Use 15 for free product

<b>Patient Segment</b> Segment Identification (NCPDP field # 111-AM) = '01'				
Field #	NCPDP Field Name	Value	Payer Usage	Payer Situation
307-C7	Place of Service	12	R	